News Sentiment

PRLD sentiment intelligence

Prelude Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 37 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.81 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 29

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-2.1% over one week, +7.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

H.C. Wainwright reiterates Prelude Therapeutics stock rating at buy By Investing.com

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -2.1% Price reacting lower
Trend fit Trend active 7.0% over four weeks
Fair value 79.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 25
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 29
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
dars.gov.et 4
simplywall.st 4
Investing.com 3
marketscreener.com 3
Stock Titan 3
GlobeNewswire 3
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 12
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 37